Developing and Validating Blood and Imaging BIOmarkers of AXonal Injury Following Traumatic Brain Injury

Developing and Validating Blood and Imaging BIOmarkers of AXonal Injury Following Traumatic Brain Injury

Sponsors

Lead Sponsor: Imperial College London

Collaborator: Centre Hospitalier Universitaire Vaudois
University College, London
Istituto Di Ricerche Farmacologiche Mario Negri
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Source Imperial College London
Brief Summary

Observational longitudinal study assessing outcomes following moderate-severe traumatic brain injury (TBI).

Detailed Description

Traumatic brain injury (TBI) occurs when the brain is physically damaged, for example after a car crash. It is common and survivors often have major on-going problems. It is very difficult to predict how patients will do after TBI. One reason for this is that clinicians and researchers are unable to measure all the effects of TBI. An important factor is that the connections between nerve cells are damaged by the impact on the brain of an injury (axonal injury). This damage has been difficult to measure in the past, but new ways to scan the brain and more sensitive ways of picking up the effects of this injury in the blood could change this. In other parts of medicine tests of this type have had a dramatic effect on how clinicians treat patients. For example, the products of heart muscle damage that have leaked into the blood can be used identify a heart attack and guide treatment. Clinicians need similar tests to be available in TBI. This should be possible as the products of axonal injury also leak into the blood and researchers have a sensitive way to pick this up. An accurate test for axonal injury would guide treatment choices and allow clinicians to predict how patients will recover. The investigators have brought together an international team who have been working on different aspects of this problem for many years. Together the investigators will conduct a large study to identify the best measures of axonal injury. The investigators will carefully test whether these measures help predict outcomes and will study where the blood markers come from using a safe method to measure the effects of axonal injury directly from the brain. The work links into some large projects that have already started and will use a standard way to assess patients after their injury. This is important because it will allow researchers to share results across studies. The investigators hope the work will allow us to identify a blood marker for TBI that could be widely used to quickly identify the presence of axonal injury. The investigators will also show what brain imaging measure is best at picking up axonal injury and how best to combine the measures to best predict how patients recover. This will allow doctors to diagnose problems after TBI more accurately, choose the right treatments and give patients and their families accurate advice about what will happen after discharge from hospital.

Overall Status Enrolling by invitation
Start Date 2017-11-30
Completion Date 2021-09-30
Primary Completion Date 2020-08-01
Study Type Observational
Primary Outcome
Measure Time Frame
Change in diffusion tensor imaging measures over time 10 days - 6 weeks, 6 months and 12 months
Brain atrophy rates 10 days - 6 weeks, 6 months and 12 months
Change in levels of fluid biomarkers in blood 0-5 days, 5-10 days, 10 days - 6 weeks, 6 months and 12 months
Change in levels of fluid biomarkers in cerebral fluid 48 hours to 7 days
Enrollment 250
Condition
Intervention

Intervention Type: Diagnostic Test

Intervention Name: MRI

Description: Magnetic Resonance Imaging

Intervention Type: Diagnostic Test

Intervention Name: Blood Sampling

Description: Sampling of serum

Intervention Type: Diagnostic Test

Intervention Name: Microdialysis

Description: Monitoring of cerebral fluid protein levels

Arm Group Label: TBI - microdialysis / adv. MRI / cognitive / clinical

Intervention Type: Diagnostic Test

Intervention Name: Neuropsychological tests

Description: Battery of tests to assess cognitive function, patient outcomes

Intervention Type: Diagnostic Test

Intervention Name: MRI (advanced)

Description: Advanced MRI

Eligibility

Sampling Method:

Non-Probability Sample

Criteria:

Inclusion Criteria: - A diagnosis of moderate/severe traumatic brain injury (TBI) as classified using the Mayo classification system; - Healthy controls will be age-matched to our TBI patients and will not have a history of significant neurological or psychiatric conditions. Exclusion Criteria: - Unwillingness or inability to follow the procedures required - Bilateral fixed dilated pupils - For MRI, contra-indication to MRI scanning, assessed by a standard pre-MRI questionnaire (e.g. presence of ferromagnetic implants in the body, claustrophobia, pregnancy) if considered for the imaging strand of the study.

Gender:

All

Minimum Age:

18 Years

Maximum Age:

80 Years

Healthy Volunteers:

Accepts Healthy Volunteers

Overall Official
Last Name Role Affiliation
David Sharp Principal Investigator Imperial College London
Location
Facility:
Fondazione IRCCS, Ca' Granda Ospedale Maggiore Policlinico | Milan, Italy
IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri" | Milan, Italy
University Medical Centre | Ljubljana, Slovenia
Centre Hospitalier Universitaire Vaudois | Lausanne, Switzerland
Imperial College London | London, W12 0NN, United Kingdom
Location Countries

Italy

Slovenia

Switzerland

United Kingdom

Verification Date

2020-07-01

Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Arm Group

Label: TBI - MRI / bloods / cognitive / clinical outcomes

Description: Work package 1. In a large multi-centre cohort of adult moderate/severe TBI patients we aim to identify the most informative plasma biomarker(s) of the severity of axonal injury. We will characterise their time course, focusing on neurofilament light (NFL) and tau, and relate these to magnetic resonance imaging (MRI) measures of axonal injury. Using logistic regression we will then test whether these measures contribute to the prediction of clinical outcome at twelve months

Label: TBI - Advanced MRI / bloods / cognitive / clinical outcomes

Description: Work package 2. In a subgroup of the patients recruited to WP1 we will use advanced MRI and longitudinal assessments to provide a more detailed description of the relationship between the plasma biomarkers and outcome after TBI. We will test whether advanced diffusion and myelin integrity measures correlate with plasma biomarkers and whether early plasma biomarker levels predict neurodegeneration measured by progressive atrophy after TBI.

Label: TBI - microdialysis / adv. MRI / cognitive / clinical

Description: Work package 3. In a second subgroup of patients recruited to WP1 we will combine microdialysis, neuroimaging and plasma sampling of axonal proteins to provide a deeper understanding of the mechanisms of axonal injury progression and use this approach to investigate the axonal origin of the plasma biomarkers.

Label: Healthy volunteer

Description: Single assessment using MRI, bloods and cognitive testing.

Acronym BIO-AX-TBI
Patient Data No
Study Design Info

Observational Model: Cohort

Time Perspective: Prospective

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News